Case Details
Name Title: Novartis AG v. Union of India (2013)
Date of Judgment: 1 April 2013
Appellant: Novartis AG
Respondent: Union of India & Others
Bench: Justice Aftab Alam and Justice Ranjana Prakash Desai
Introduction
The Novartis case is the most significant judgment in Indian patent law. This case revolves around the interpretation and application of Section 3(d) of Indian patent act,1970, which states that ‘the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant’.
To grant patents for new forms of known substances, they must demonstrate the required enhancement in efficacy.
The dispute arose when pharmaceutical company Novartis AG sought a patent for the b-crystalline form of Imatinib Mesylate, the active ingredient associated with its anti-cancer drug Glivec, and the Supreme Court rejected it, claiming that Novartis’s form did not satisfy the enhanced-efficacy requirement under Section 3(d).
Facts of the Case
Novartis is a multinational pharmaceutical company with headquarters in Switzerland and developed a drug used to cure chronic myeloid leukaemia and certain other cancers, named imatinib mesylate, and claimed that it is the b-crystalline form of the drug Glivec. Later in 1997, Novartis filed a patent in India for the b-crystalline form of Imatinib Mesylate.
The Indian Patent Office rejected Novartis’s application. Novartis challenged this decision before the Madras High Court and then before the Intellectual Property Appellate Board (IPAB). The IPAB held that the claimed invention satisfied the requirements of novelty and inventive step but failed to satisfy Section 3(d) because there was no sufficient enhancement of efficacy.
Issue Before the Court
The issue before the court was:
- Whether the b-crystalline form was merely a new form of a known substance and therefore fell within Section 3(d).
- How should efficacy be interpreted under Section 3(d) of the Patent Act?
- Whether the new form of the known substance results in enhanced therapeutic efficacy, as required by Section 3(d).
- Whether the b-crystalline form demonstrated the required enhancement of known efficacy.
- Arguments by Novartis AG (Appellant):
Novartis AG contended that the b-crystalline form of Imatinib Mesylate is a new form and a true and new invention and therefore constitutes a patentable invention.
The appellant also argued that the invention satisfied the requirements of novelty and an inventive step under Sections 2(1)(j) and 2(1)(ja) of the Patents Act.
The appellant also questioned the clarity of the expression “enhancement of known efficacy.” It stated that denying such patents would deter innovation in India’s pharmaceutical sector.
- Arguments by Respondent:
Union of India and other respondents objected to the grant of the patent.
The respondent stated that Imatinib Mesylate was already disclosed in the prior art and is not a new form; hence, it can’t be patented.
The respondent also argued that Section 3(d) was introduced to prevent pharmaceutical companies from obtaining repeated patents for minor modifications of existing medicines; this could lead to the creation of a monopoly over medicines by the pharmaceutical companies.
Respondent further highlighted that developing nations require affordable medicines, as generic medicines play a significant role in the public domain.
Supreme Court Judgment
The Supreme Court dismissed Novartis AG’s appeal and refused to grant a patent for the b-crystalline form of Imatinib Mesylate. It clearly stated that this is not a new form of the drug because the prior art had already disclosed it. Hence, the from failed to satisfy the requirements under Section 3(d) of the Indian Patents Act, 1970.
The court further stated that, under Section 2 (1)(j) of the Indian Patents Act, 1970, to grant a patent, there are three necessary requirements that need to be fulfilled.
Three requirements are:
- The invention must be new, i.e., must possess novelty.
- There must be an inventive step in the invention; it must not be previously disclosed and must not be obvious.
- The invention must be capable of industrial application.
As a result, it was decided that imatinib mesylate’s beta-crystalline form did not meet the inventiveness and patentability tests. The Supreme Court ruled that it lacked originality and hence the Novartis AG appeal was dismissed.
Significance of Judgment
The Novartis AG judgment is one of the most important cases for understanding the interpretation of Section 3(d) of the Indian Patents Act, 1970.
It is also important for pharmaceutical companies, which tend to seek a patent, to understand that merely making minor modifications to an existing drug does not fulfil the requirements for the grant of a patent.
This judgment also prevents the unwarranted extensions of pharmaceutical monopolies; Section 3(d) can facilitate the continued availability of generic alternatives after legitimate patent rights expire and maintain a balance between two competing interests, i.e. innovation and public interest.
Conclusion
Novartis AG v. Union of India is a landmark decision in Indian patent law and in the pharmaceutical sector. It clarified that not every modification of an existing pharmaceutical substance is entitled to a new patent.
The Supreme Court held that the b-crystalline form of Imatinib Mesylate failed to demonstrate the requirements under Section 3(d) of the Patents Act, 1970.
This judgment reinforced the principle that patent protection must be based on novelty and distinctiveness rather than a slight change in an already existing substance.
The decision continues to be cited in international debates on health, innovation, and intellectual property. It remains significant for understanding the relationship between patentability, pharmaceutical innovation, Section 3(d), evergreening, and access to medicines in India.
Reference
- Novartis AG v. Union of India & Others (1 April 2013).
- https://indiankanoon.org/doc/165776436/
- The Patents Act, 1970, Sections 2(1)(j), 2(1)(ja) and 3(d).
